Inhibikase Therapeutics, INC. (IKT) — 8-K Filings

8-K Filings (23)

• Inhibikase Therapeutics Files 8-K — Apr 7, 2026 Risk: medium
  Inhibikase Therapeutics, Inc. filed an 8-K on April 7, 2026, reporting under Regulation FD Disclosure and Financial Statements and Exhibits. The filing includes
• 8-K Filing — Dec 19, 2025
• 8-K Filing — Nov 21, 2025
• Inhibikase Therapeutics Files 8-K Report — Nov 20, 2025 Risk: low
  On November 20, 2025, Inhibikase Therapeutics, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 1000 N. W
• Inhibikase Therapeutics Reports Shareholder Vote — Jun 30, 2025 Risk: medium
  Inhibikase Therapeutics, Inc. filed an 8-K on June 30, 2025, reporting on a matter submitted to a vote of its security holders on June 27, 2025. The filing does
• Inhibikase Therapeutics Files 8-K on Financials — May 14, 2025 Risk: low
  Inhibikase Therapeutics, Inc. filed an 8-K on May 14, 2025, reporting on its results of operations and financial condition. The filing includes financial statem
• Inhibikase Therapeutics Announces Corporate Changes — Apr 14, 2025 Risk: medium
  Inhibikase Therapeutics, Inc. announced on April 11, 2025, a series of significant corporate actions. These include the departure of certain officers and direct
• Inhibikase Therapeutics Files 8-K on Financials — Mar 27, 2025 Risk: low
  Inhibikase Therapeutics, Inc. filed an 8-K on March 27, 2025, reporting on its results of operations and financial condition. The filing also includes financial
• Inhibikase Therapeutics Files 8-K with Key Corporate Updates — Feb 24, 2025 Risk: medium
  Inhibikase Therapeutics, Inc. announced on February 21, 2025, the entry into a material definitive agreement. The company also reported on unregistered sales of
• Inhibikase Therapeutics Files 8-K on Officer/Director Changes — Feb 18, 2025 Risk: medium
  Inhibikase Therapeutics, Inc. filed an 8-K on February 18, 2025, reporting events as of February 13, 2025. The filing covers the departure of directors or certa
• Inhibikase Therapeutics Files 8-K Report — Jan 29, 2025 Risk: low
  On January 29, 2025, Inhibikase Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and does not detail specific transactions o
• Inhibikase Therapeutics Files 8-K — Jan 6, 2025 Risk: low
  Inhibikase Therapeutics, Inc. filed an 8-K on January 6, 2025, reporting events that occurred on January 3, 2025. The filing indicates amendments to its Article
• Inhibikase Therapeutics Terminates Material Agreement — Dec 5, 2024 Risk: medium
  Inhibikase Therapeutics, Inc. announced on December 2, 2024, the termination of a material definitive agreement. The company, incorporated in Delaware, is based
• Inhibikase Therapeutics Files 8-K on Agreements and Personnel Changes — Oct 22, 2024 Risk: medium
  Inhibikase Therapeutics, Inc. filed an 8-K on October 21, 2024, reporting on the entry into a material definitive agreement, the departure of directors or offic
• Inhibikase Therapeutics Announces CMO Departure, Interim Appointment — Oct 10, 2024 Risk: medium
  On October 9, 2024, Inhibikase Therapeutics, Inc. announced the departure of Dr. Jonathan P. S. Walsh as Chief Medical Officer and the appointment of Dr. Michae
• Inhibikase Therapeutics Files 8-K — Oct 9, 2024 Risk: low
  Inhibikase Therapeutics, Inc. filed an 8-K on October 9, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not c
• Inhibikase Therapeutics Files 8-K on Shareholder Votes — Aug 6, 2024 Risk: low
  Inhibikase Therapeutics, Inc. filed an 8-K on August 5, 2024, to report on matters submitted to a vote of its security holders. The filing details the company's
• Inhibikase Therapeutics Reports on Shareholder Vote Matters — Jun 10, 2024 Risk: low
  Inhibikase Therapeutics, Inc. filed an 8-K on June 10, 2024, reporting on a submission of matters to a vote of security holders that occurred on June 7, 2024. T
• Inhibikase Therapeutics Files 8-K with Material Agreements — May 20, 2024 Risk: medium
  On May 20, 2024, Inhibikase Therapeutics, Inc. entered into a material definitive agreement, likely related to its business operations. The company also disclos
• Inhibikase Therapeutics Files 8-K — Apr 30, 2024 Risk: low
  Inhibikase Therapeutics, Inc. filed an 8-K on April 30, 2024, reporting events as of April 26, 2024. The filing includes information related to Regulation FD di
• Inhibikase Therapeutics Files 8-K for 'Other Events' — Feb 7, 2024
  Inhibikase Therapeutics, Inc. filed an 8-K on February 7, 2024, to report 'Other Events' and 'Financial Statements and Exhibits.' This filing indicates that the
• Inhibikase Therapeutics Reports Material Definitive Agreement — Feb 1, 2024
  Inhibikase Therapeutics, Inc. (IKT) filed an 8-K on February 1, 2024, to report entering into a material definitive agreement. This filing indicates a significa
• Inhibikase Therapeutics 8-K: Executive Comp & Officer Changes — Jan 16, 2024
  Inhibikase Therapeutics, Inc. filed an 8-K on January 16, 2024, to report changes in its executive compensation arrangements and potentially the departure or el

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX